But the company’s shares surged more than 400% after an investment group led by Shkreli purchased a majority stake in the struggling firm.
Advertisement
Bryant ‘s double-double carries Lakers past Celtics, 112-104
Then LeBron James and the Cavaliers played here for the first time since sweeping the Celtics out of the first round last season. The guys were looking at me like, ‘What is wrong? But something was still missing, especially for Kobe who was named Finals MVP.
The move comes after Shkreli, its former CEO, was charged on December 17 in federal court with securities fraud related to a hedge fund and another company.
Eagles CEO Jeffrey Lurie says coach following Chip Kelly needs people skills
By letting Kelly go a week before the end of the regular season, the Eagles will get a head start on their coaching search. Eagles owner Jeffrey Lurie made it official with a letter to season-ticket holders that also served as a news release.
Major creditors of the pharmaceutical company included accounting firm Ernst & Young, as well as the University of Miami, California’s Cedars-Sinai Medical Center, The Cleveland Clinic Foundation, the Mayo Clinic and other medical research centers.
New ‘Star Wars’ movie has record M opening night
The White House got in on the action, too, sharing the stage with a stormtrooper at Friday’s press briefing. Greenfield said the success of ” Force Awakens ” would not offset the impact of subscriber losses at ESPN.
Another Shkreli associate, Chris Thorn, KaloBios’ interim chief financial officer, resigned from KaloBios before Christmas.
Turing, though laying off and lacking a CEO, isn’t in as critical a condition as KaloBios, which in light of the arrest is being delisted from Nasdaq and its shares suspended. There were reports that Turing’s CEO is in talks with KaloBios about continuing operations, considering its development of cancer drugs.
Read the Bloomberg article, Shkreli’s Former Biotech Company KaloBios Files for Bankruptcy.
The company plans to use the bankruptcy period to “evaluate its strategic alternatives” and to develop a restructuring plan, according to documents filed with the United States bankruptcy court for the District of Delaware.
Shkreli gained notoriety when, as the chief executive of Turing Pharmaceuticals, he raised the price of a drug used to treat a unsafe parasitic infection to $750 a tablet from $13.50. Marcum had audited Retrophin Inc.-a company that Shkreli founded but which is suing him-during the 2013 period when transactions occurred that are now the subject of charges by the SEC and the Justice Department.
Shkreli, 32, is accused of repeatedly losing money for investors and lying to them about it, as well as illegally taking assets from Retrophin to pay off some of those investors.
KaloBios said Tuesday that it has requested an appeal of the decision to delist its securities.
Advertisement
Tom Fernandez and Marek Biestek resigned on Sunday, according to a securities filing.
